• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BUD

    Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

    Subscribe to $BUD
    $BUD
    Beverages (Production/Distribution)
    Consumer Staples

    Anheuser-Busch InBev SA/NV engages in the production, distribution, and sale of beer, alcoholic beverages, and soft drinks worldwide. It offers a portfolio of approximately 500 beer brands, which primarily include Budweiser, Corona, and Stella Artois; Beck's, Hoegaarden, Leffe, and Michelob Ultra; and Aguila, Antarctica, Bud Light, Brahma, Cass, Castle, Castle Lite, Cristal, Harbin, Jupiler, Modelo Especial, Quilmes, Victoria, Sedrin, and Skol brands. The company was founded in 1366 and is headquartered in Leuven, Belgium. Anheuser-Busch InBev SA/NV is a subsidiary of AB InBev NV/SA.

    IPO Year:

    Exchange: NYSE

    Website: ab-inbev.com

    Recent Analyst Ratings for Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

    DatePrice TargetRatingAnalyst
    5/12/2025$88.00Neutral → Buy
    Goldman
    4/2/2025Buy
    Berenberg
    3/27/2025$70.00Hold → Buy
    Argus
    3/3/2025Hold → Buy
    Deutsche Bank
    10/8/2024$88.00Buy → Hold
    TD Cowen
    10/1/2024Neutral → Buy
    Citigroup
    6/24/2024Neutral → Buy
    UBS
    1/12/2024Outperform → Neutral
    Exane BNP Paribas
    1/10/2024Hold → Buy
    Jefferies
    12/5/2023Sell → Neutral
    UBS
    See more ratings